Rigel Pharmaceuticals, Inc.
(NASDAQ : RIGL)

( )
RIGL PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.17%203.561.3%$427.08m
BIIBBiogen Inc.
-0.93%225.601.3%$388.53m
GILDGilead Sciences, Inc.
-0.18%65.230.9%$367.43m
CELGCelgene Corporation
0.82%101.801.3%$356.32m
ILMNIllumina, Inc.
0.28%310.553.5%$253.40m
REGNRegeneron Pharmaceuticals, Inc.
0.73%301.572.6%$219.86m
EXASExact Sciences Corporation
-0.20%97.3924.1%$203.99m
ALXNAlexion Pharmaceuticals, Inc.
0.48%99.992.0%$181.39m
VRTXVertex Pharmaceuticals Incorporated
0.93%177.721.9%$178.93m
AAgilent Technologies, Inc.
-0.47%74.921.6%$143.96m
SRPTSarepta Therapeutics, Inc.
0.81%87.4414.6%$138.15m
BMRNBioMarin Pharmaceutical Inc.
-0.06%67.904.3%$95.86m
SGENSeattle Genetics, Inc.
2.48%85.946.2%$90.55m
NKTRNektar Therapeutics
1.31%17.775.5%$84.92m
ALDRAlder Biopharmaceuticals, Inc.
0.16%18.9010.2%$83.36m

Company Profile

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. Its products include Tavalisse, Fostamatinib and R835. The company was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.